This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
November 2, 2016 – Verastem, Inc. and Infinity Pharmaceuticals, Inc., today announced that the companies entered into a license agreement under which Verastem licensed exclusive worldwide rights to develop and commercialize Infinity’s oncology product candidate duvelisib. Duvelisib is an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma being investigated for the treatment of hematologic cancers, including chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma (iNHL) and T cell lymphomas.
“Duvelisib is a clinically validated, late-stage product candidate with a proven mechanism of action. Topline data from the DUO study is expected in the first half of 2017.” said Robert Forrester, President and Chief Executive Officer of Verastem. “The potential of duvelisib is supported by clinical data demonstrating anti-cancer activity and a manageable safety profile in a wide range of lymphoid malignancies, including relapsed/refractory iNHL, CLL and T cell lymphomas,” said Gregory I. Berk, MD, Chief Medical Officer of Verastem. “While there have been significant advances recently in the treatment of lymphoid malignancies, not all patients experience benefits or can tolerate these treatments. There remains a need for new oral medicines, and the targeted inhibition of PI3K-delta and PI3K-gamma brings a unique approach designed to address both the malignant B cell and its supportive microenvironment. We look forward to reporting data from the DUO study, which could enable a submission for regulatory approval.”